Skip to main content
    L

    Larimar Therapeutics Inc (LRMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.99
    -0.01 (-0.33%)

    Market Cap: $311.65M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Larimar Therapeutics Inc (LRMR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Larimar Therapeutics (LRMR) has a market cap of $311.65M and an enterprise value of $234.66M. Its share count is up 33.69% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 24.70% below the market cap, as cash exceeds debt.

    Market Cap$311.65M
    Enterprise Value$234.66M
    Latest price (Nov 17, 2026)$2.99

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.31% in the quarter ended Sep 30, 2026 and grew 28.10% a year over 2 years.

    Shares Outstanding104.71M
    Shares Change (YoY)+33.69%
    Shares Change (QoQ)+0.31%
    Share Count Growth (2Y CAGR)+28.10%

    Price Statistics

    The stock is down 11.54% over 52 weeks and trades 3.10% above its 50-day average.

    Beta (1Y)1.91
    52-Week Change-11.54%
    1-Month Change+41.04%
    3-Month Change-29.65%
    6-Month Change-10.21%
    5-Year Change-79.33%
    10-Year Change-93.16%
    Total Return (1Y)-11.54%
    Total Return (3Y CAGR)-3.14%
    Total Return (5Y CAGR)-21.96%
    Return vs SPY (1Y)-23.36%
    Max Drawdown (1Y)-66.64%
    Max Drawdown (3Y)-87.12%
    Sharpe Ratio (1Y)-0.14
    Correlation with SPY (1Y)0.28
    50-Day Average$2.90
    200-Day Average$3.76
    52-Week Range$1.92 to $6.42
    RSI (14 Days)58.6
    Average Volume (20 Days)1.35M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.82x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.82x
    Quick Ratio3.82x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -153.77% over the last 12 months, against a 5-year average of -82.96%.

    Return on Equity (ROE)-153.77%
    Return on Assets (ROA)-111.05%
    Return on Capital Employed (ROCE)-151.68%
    ROE (5Y Average)-82.96%
    ROA (5Y Average)-56.94%

    Scores

    LRMR has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$87.00K
    Operating Income-$161.95M
    Pretax Income-$164.36M
    Net Income-$156.03M
    EBITDA-$159.92M
    EBIT-$159.05M
    Reported EPS (TTM)-$1.63

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.22% of the $140.50M in total assets.

    Cash and Equivalents$76.99M
    Total Debt$0
    Net Cash$76.99M
    Net Cash Per Share$0.74
    Working Capital$100.51M
    Shareholder Equity$101.47M
    Book Value Per Share$0.97
    Total Assets$140.50M
    Total Liabilities$39.04M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $158.00K of capital spending, operating cash flow left -$233.19M of free cash flow.

    Operating Cash Flow-$233.03M
    Capital Expenditures$158.00K
    Free Cash Flow-$233.19M
    FCF Per Share-$2.24
    Depreciation and Amortization$1.41M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    LRMR does not pay a dividend. Its free cash flow yield is -74.48%.

    FCF Yield-74.48%
    Buyback Yield-35.30%
    Shareholder Yield-35.30%

    Stock Splits

    The last split was a 1-for-12 reverse split on May 29, 2020.

    Last Split DateMay 29, 2020
    Split TypeReverse split
    Split Ratio1:12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About LRMR

    What is LRMR's market cap?

    Larimar Therapeutics has a market cap of $311.65M. Its enterprise value, which adds debt and subtracts cash, is $234.66M.

    How many shares of LRMR are outstanding?

    Larimar Therapeutics has 104.71M shares outstanding. The count is up 33.69% from a year earlier.

    Does LRMR pay a dividend?

    No. Larimar Therapeutics does not pay a dividend.

    How much debt does LRMR have?

    Larimar Therapeutics has $0 of total debt and $76.99M of cash and equivalents, a net cash position of $76.99M.